10. REFERENCES

- Birkett DJ. ‘Generics equal or not’. *Australian Prescriber* 2003; **26**: 85-7


Donovan J. Is there a role for generic medicines in the pharmaceutical benefits scheme? Health Issues 2003; 73; 9-11.


Figueiras MJ, Marcelino D, Cortes MA. People’s views on the level of agreement of generic medicines for different illnesses. Pharmacy World &Science 2008; 30; 590-4.


References

- Gupta AS. IMPF Policy Notes for Parliamentarians on access to medicines. Series No.'1 New Delhi-110011: Centre for legislation and Advocacy 2007 August. p.6 (impf@clairindia.org www.impf.in)
References

- Kesselheim AS, Alexander SM, Joy LL, Margreet RS, Brookhart MA, Choudhry NK et al., Clinical Equivalence of Generic and Brand Name Drugs Used in


Mathew JC. “Courts being used to stifle generic challengers.” *IDMA Bulletin* 2009 Aug 30; **XL (32)**: 60.


Meyer GF. History and regulatory issues of generic drugs. *Transplantation Proceedings* 1999 May; **31 (suppl 3A)**: 10S-12S.


Pandey V. Produce details of freebies to doctors, Medical Council of India to pharma companies *IDMA Bulletin* 2010 Apr 01-07; **(XLI) 13**: 41.


· Pingle S. Japanese cos steps up R & D expenditure. *Chronicle Pharmabiz* 2010 June 24; **10 (28)**: 14

· Probyn A. Some drugs more equal than others: *Pseudogenerics and Commercial Practice* 2004; **28(2)**: 207-17.


· Saigura O. Japan’s healthcare system and pharmaceutical industry. *Journal of Generic Medicines* 2006; **4**: 23-9.


· Shafie AA, Hassali MA. Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang, Malaysia. *Journal of Generic Medicines* 2008; **6**: 35-42.

· Shankar R. DoP opened only 55 Jan Aushadhi stores till March 2010, target set was 276. *Chronicle Pharmabiz* 2010 June 17; **10(27)**: 19.

· Shankar R. Health Ministry issues directives to Government doctors to prescribe generic drugs. *Chronicle Pharmabiz* 2010 July 1; **10(29)**: 19.
References


- Singh K. MNCs back in control of 50% of Indian pharma market. *IDMA Bulletin* 2010 May 22-30; **XLI** (20): 20-1.


http://www.artsandopinion.com Assessed on April 2, 2011
http://www.boletinfarmacos.org/ Assessed on Feb.25,2011
http://www.cdsco.nic.in Assessed on April 2,2011
http://www.cgpa.comAssessed on Dec.11,2010
http://www.en.wikipedia.org/wiki/Pharmaceutical_industry_in_China
http://www.eng.sfda.gov Assessed on Dec.11,2010
http://www.fda.gov Assessed on April 2,2011
http://www.fda.gov/cder/ob/ Assessed on Dec.6,2010
http://www.fda.gov/cder/ord Assessed on Dec. 6,2010
http://www.fda.gov/cder/ogd/Assessed on Dec.6,2010
http://www.fda.gov/forms/fdaforms.htm Assessed on April 2,2011
http://www.fda.gov/RegulatoryInformation/legislation/Federal Assessed on Dec 6,2010
http://www.haiweb.org/medicineprices/ Assessed on Feb.25,2011
http://www.imshealth.com/ims/portal/front/article/02777,6599_62451903,00.html Assessed on Dec. 6,2010
URL://www.imshealth.com/portal/site/imshealth/menuitemAssessed on Feb 25,2011
URL://www.hma.eu/ Assessed on Feb.25,2011
http://www.kingandwood.com Assessed on Dec.11,2010
http://www.law.duke.edu/journals/dlitr/articles/2003dlitr0018.hAssessed on Dec.6, 2010
http://www.managingip.com Assessed on Dec.6,2010
http://www.nafdacnigeria.org/publichealth.html Assessed on Feb 12,2011
http://www.oig.hhs.gov Assessed on April 2,2011
http://www.prescribersletter.com Assessed on Feb 25,2011
References

- http://www.tribuneindia.com Assessed on Dec. 6, 2010